[go: up one dir, main page]

GT199800158AA - PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS - Google Patents

PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS

Info

Publication number
GT199800158AA
GT199800158AA GT199800158AK GT199800158K GT199800158AA GT 199800158A A GT199800158A A GT 199800158AA GT 199800158A K GT199800158A K GT 199800158AK GT 199800158 K GT199800158 K GT 199800158K GT 199800158A A GT199800158A A GT 199800158AA
Authority
GT
Guatemala
Prior art keywords
prostaglandin agonists
bone disorders
treat bone
prostaglandin
agonists
Prior art date
Application number
GT199800158AK
Other languages
Spanish (es)
Inventor
Kimberly O'keefe Cameron
Bruce Allen Lefker
Robert Louis Rosati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199800158AA publication Critical patent/GT199800158AA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrrole Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A AGONISTAS DE PROSTAGLANDINAS, PROCEDIMIENTOS DE USO DE DICHOS AGONISTAS DE PROSTAGLANDINAS, COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS AGONISTAS DE PROSTAGLANDINAS Y ESTUCHES DE ENSAYO QUE CONTIENEN DICHOS AGONISTAS DE PROSTAGLANDINAS. LOS AGONISTAS DE PROSTAGLANDINAS SON UTILES PARA EL TRATAMIENTO DE LOS TRASTORNOS OSEOS, INCLUYENDO LA OSTEOPOROSIS.THIS INVENTION IS REFERRED TO PROSTAGLANDIN AGONISTS, PROCEDURES FOR THE USE OF SUCH PROSTAGLANDIN AGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH PROSTAGLANDIN AGONISTS AND CONTAINING TEST CASES OF SUCH AGGONTAINS. PROSTAGLANDIN AGONISTS ARE USEFUL FOR THE TREATMENT OF BONE DISORDERS, INCLUDING OSTEOPOROSIS.

GT199800158AK 1997-10-10 1998-10-09 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS GT199800158AA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6172797P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
GT199800158AA true GT199800158AA (en) 2000-04-01

Family

ID=22037728

Family Applications (2)

Application Number Title Priority Date Filing Date
GT199800158AK GT199800158AA (en) 1997-10-10 1998-10-09 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS
GT199800158A GT199800158A (en) 1997-10-10 1998-10-09 PROSTAGLANDIN AGONISTS.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GT199800158A GT199800158A (en) 1997-10-10 1998-10-09 PROSTAGLANDIN AGONISTS.

Country Status (44)

Country Link
US (2) US6498172B1 (en)
EP (1) EP1021410B1 (en)
JP (3) JP3664651B2 (en)
KR (1) KR100369697B1 (en)
CN (2) CN1566096A (en)
AP (1) AP1156A (en)
AR (1) AR015954A1 (en)
AT (1) ATE349428T1 (en)
AU (1) AU731509B2 (en)
BG (1) BG65238B1 (en)
BR (1) BR9813028A (en)
CA (1) CA2305548C (en)
DE (1) DE69836752T2 (en)
DK (1) DK1021410T3 (en)
DZ (1) DZ2621A1 (en)
EA (1) EA003396B1 (en)
ES (1) ES2277390T3 (en)
GT (2) GT199800158AA (en)
HN (1) HN1998000157A (en)
HR (1) HRP20000201B1 (en)
HU (1) HUP0100101A3 (en)
ID (1) ID24836A (en)
IL (2) IL134851A0 (en)
IS (1) IS5405A (en)
MA (1) MA26551A1 (en)
MY (1) MY129189A (en)
NO (1) NO316733B1 (en)
NZ (1) NZ503165A (en)
OA (1) OA11346A (en)
PA (1) PA8461301A1 (en)
PE (1) PE121199A1 (en)
PL (1) PL340014A1 (en)
PT (1) PT1021410E (en)
RS (1) RS50012B (en)
SA (2) SA98190804B1 (en)
SI (1) SI1021410T1 (en)
SK (1) SK286136B6 (en)
TN (1) TNSN98182A1 (en)
TR (1) TR200000927T2 (en)
TW (1) TW570913B (en)
UA (1) UA67754C2 (en)
UY (1) UY25204A1 (en)
WO (1) WO1999019300A1 (en)
ZA (1) ZA989230B (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (en) 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders
EP1000619A3 (en) * 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
CN1350521A (en) 1999-03-05 2002-05-22 宝洁公司 C16 unsaturated FP-selective prostaglanding analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
AU2002365969A1 (en) * 2001-11-20 2003-06-10 Scott Bruder Flowable osteogenic and chondrogenic compositions
CN1599605A (en) * 2001-11-30 2005-03-23 辉瑞产品公司 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
BR0214610A (en) * 2001-11-30 2004-09-14 Pfizer Controlled release polymeric compositions of bone growth promoting compounds
OA12760A (en) * 2002-01-31 2006-07-04 Pfizer Prod Inc Metabolites of (3-ÄÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylÜ-phenoxy)-acetic acid.
MXPA04009960A (en) * 2002-04-12 2004-12-13 Pfizer Pyrazole compounds as anti-inflammatory and analgesic agents.
MXPA04011691A (en) 2002-05-24 2005-09-12 Pharmacia Corp Anilino liver x-receptor modulators.
EP1511723A1 (en) 2002-05-24 2005-03-09 Pharmacia Corporation Sulfone liver x-receptor modulators
JP2006021998A (en) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Treatment for dysmenorrhea containing EP2 agonist as an active ingredient
ES2393321T3 (en) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promoters of the production of endogenous repair factors
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
KR20050105511A (en) * 2003-03-04 2005-11-04 화이자 프로덕츠 인크. Use of ep2 selective receptor agonists in medical treatment
EP1661580B1 (en) 2003-07-25 2014-01-08 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
CA2571482A1 (en) * 2004-06-21 2005-12-29 Pharmacia & Upjohn Company Llc Pyk2 inhibitors for stimulation of osteoblast function
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN103102303B (en) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 As the benzyl amine derivative of CETP inhibitor
CA2610692C (en) 2005-06-03 2014-11-25 Ono Pharmaceutical Co., Ltd. Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
CA2659184C (en) * 2006-07-28 2012-02-21 Pfizer Products Inc. Ep2 agonists
UA94953C2 (en) * 2006-07-28 2011-06-25 Пфайзер Продактс Инк. Ep2 agonists
CA2669763C (en) 2006-11-16 2015-02-17 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
US9394520B2 (en) * 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
CN101828111B (en) * 2007-08-21 2014-07-23 塞诺米克斯公司 Human T2R bitter receptors and uses thereof
CN101842356A (en) * 2007-08-29 2010-09-22 辉瑞产品公司 Polymorphs of (3- (((4-tert-butylbenzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or hydrate thereof and process for producing the same
US20110046385A1 (en) * 2007-08-29 2011-02-24 Pfizer Products Inc. Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
WO2009027803A2 (en) * 2007-08-29 2009-03-05 Pfizer Products Inc. Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
SI2264009T1 (en) * 2008-03-12 2019-05-31 Ube Industries, Ltd. Pyridylaminoacetic acid compound
EP2149551A1 (en) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors
EP2149552A1 (en) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituted benzamide derivatives as modulators of EP2 receptors
EP2149554A1 (en) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolyamides as modulators for an EP2 receptor
SI2415763T1 (en) 2009-03-30 2016-05-31 Ube Industries, Ltd. Pharmaceutical composition for treating or preventing glaucoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
CN102666490A (en) 2009-12-25 2012-09-12 宇部兴产株式会社 Aminopyridine compound
KR101362639B1 (en) 2010-09-16 2014-02-13 연세대학교 산학협력단 Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes
JP5964965B2 (en) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド Substituted heterocyclic amine compounds as cholesteryl ester transfer protein (CETP) inhibitors
CN103958511A (en) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
US8772541B2 (en) * 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CN105143187B (en) 2013-02-28 2018-04-03 武田药品工业株式会社 The method for preparing sulfonyl chloride compound
JPWO2014157672A1 (en) 2013-03-28 2017-02-16 宇部興産株式会社 Substituted biaryl compounds
WO2015056504A1 (en) 2013-10-15 2015-04-23 小野薬品工業株式会社 Drug-eluting stent graft
JP2017206444A (en) * 2014-09-26 2017-11-24 宇部興産株式会社 Substituted phenyl compound
CN114591227A (en) * 2021-12-28 2022-06-07 上海冬洋生物科技有限公司 Preparation method of prostaglandin E2 agonist with EP2 receptor selectivity

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (en) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Rotor machine
US3442890A (en) 1965-06-15 1969-05-06 Mead Johnson & Co Substituted 3-benzazocin-16-ones
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
JPS5019756A (en) 1973-06-25 1975-03-01
SE7414770L (en) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (en) 1974-08-30 1976-03-01 Merck & Co Inc PROCEDURE FOR THE PREPARATION OF ARYLOXY OR ARYLTHIO-CONTAINING SECOPROSTAGLANDINS
US4055596A (en) * 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (en) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim NEW SULPHONAMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3042482A1 (en) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-BENZOYL- (OMEGA) -ANILINOALCANCARBONIC ACIDS, SALTS AND -ESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
CA1214170A (en) 1981-06-16 1986-11-18 Patrick Choay Preparation of novel compounds of the arylbenzenesufonamide tupe
DK373383A (en) 1982-08-20 1984-02-21 Midit PROCEDURE FOR THE PREPARATION OF OMEGA AMINO ACID DERIVATIVES
DE3719046A1 (en) 1987-06-06 1988-12-15 Basf Ag USE OF SALTS OF SULFONAMIDE CARBONIC ACIDS AS CORROSION INHIBITORS IN AQUEOUS SYSTEMS
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5081152A (en) 1989-07-05 1992-01-14 Kotobuki Seiyaku Co., Ltd. Azulene derivatives as thromboxane a2 and prostaglandin endoperoxide receptor antagonist
JPH0467105A (en) * 1990-07-09 1992-03-03 Nippon Telegr & Teleph Corp <Ntt> Polarization maintaining optical fiber
GB9110722D0 (en) * 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
GB9116732D0 (en) * 1991-08-02 1991-09-18 Fujisawa Pharmaceutical Co Indole derivatives
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
DE19648793A1 (en) 1996-11-26 1998-05-28 Basf Ag New benzamides and their application
UA59384C2 (en) * 1996-12-20 2003-09-15 Пфайзер, Інк. Preventing bone mass loss and recovery thereof by means of prostaglandin agonists
AUPO440696A0 (en) * 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. New use
UA67754C2 (en) 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders
CN1599605A (en) * 2001-11-30 2005-03-23 辉瑞产品公司 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
OA12760A (en) * 2002-01-31 2006-07-04 Pfizer Prod Inc Metabolites of (3-ÄÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylÜ-phenoxy)-acetic acid.

Also Published As

Publication number Publication date
BR9813028A (en) 2000-08-15
SA98190804B1 (en) 2006-07-30
HRP20000201B1 (en) 2003-06-30
CN1211367C (en) 2005-07-20
TW570913B (en) 2004-01-11
ZA989230B (en) 2000-04-10
GT199800158A (en) 2000-04-01
SK286136B6 (en) 2008-04-07
RS50012B (en) 2008-09-29
HRP20000201A2 (en) 2000-06-30
MA26551A1 (en) 2004-12-20
DZ2621A1 (en) 2003-03-08
SK4752000A3 (en) 2001-05-10
PL340014A1 (en) 2001-01-15
DE69836752T2 (en) 2007-10-11
JP3664651B2 (en) 2005-06-29
JP2004155759A (en) 2004-06-03
US20030078261A1 (en) 2003-04-24
EA003396B1 (en) 2003-04-24
EP1021410B1 (en) 2006-12-27
HUP0100101A2 (en) 2001-06-28
KR100369697B1 (en) 2003-02-05
CA2305548A1 (en) 1999-04-22
CN1275123A (en) 2000-11-29
JP4796006B2 (en) 2011-10-19
JP2001519414A (en) 2001-10-23
JP4031736B2 (en) 2008-01-09
AP9801356A0 (en) 1998-12-31
SI1021410T1 (en) 2007-06-30
AR015954A1 (en) 2001-05-30
BG65238B1 (en) 2007-09-28
KR20010031035A (en) 2001-04-16
TR200000927T2 (en) 2000-11-21
NZ503165A (en) 2001-07-27
DK1021410T3 (en) 2007-04-02
BG104315A (en) 2000-12-29
HUP0100101A3 (en) 2001-12-28
SA98190804A (en) 2005-12-03
JP2007246532A (en) 2007-09-27
HN1998000157A (en) 1999-06-02
IS5405A (en) 2000-03-14
CN1566096A (en) 2005-01-19
PA8461301A1 (en) 2000-05-24
AU9181598A (en) 1999-05-03
CA2305548C (en) 2008-12-02
NO20001754L (en) 2000-06-07
ATE349428T1 (en) 2007-01-15
IL134851A0 (en) 2001-05-20
ES2277390T3 (en) 2007-07-01
DE69836752D1 (en) 2007-02-08
UA67754C2 (en) 2004-07-15
UY25204A1 (en) 2000-12-29
WO1999019300A1 (en) 1999-04-22
OA11346A (en) 2003-12-11
IL134851A (en) 2007-06-17
AP1156A (en) 2003-06-30
PE121199A1 (en) 1999-12-02
YU18400A (en) 2003-08-29
TNSN98182A1 (en) 2005-03-15
HK1031884A1 (en) 2001-06-29
US7442702B2 (en) 2008-10-28
US6498172B1 (en) 2002-12-24
MY129189A (en) 2007-03-30
SA06260449B1 (en) 2007-08-07
NO316733B1 (en) 2004-04-14
EP1021410A1 (en) 2000-07-26
ID24836A (en) 2000-08-24
PT1021410E (en) 2007-02-28
EA200000298A1 (en) 2000-10-30
AU731509B2 (en) 2001-03-29
NO20001754D0 (en) 2000-04-05

Similar Documents

Publication Publication Date Title
GT199800158AA (en) PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS
PA8452701A1 (en) PROSTAGLANDIN AGONISTS
AR005987A1 (en) COMBINED THERAPY FOR OSTEOPOROSIS
CO4910163A1 (en) PREVENTION OF THE LOSS AND RESTORATION OF THE BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS
ES2139959T3 (en) STYLENE DERIVATIVES USEFUL AS CYCLOOXYGENASE-2 INHIBITORS.
BR9804437A (en) Compounds for osteoporosis
MX9709874A (en) N- (INDOL-2-CARBONYL) beta-ALANYLAMIDES SUBSTITUTED AND DERIVED AS INHIBITORS OF GLUCOGEN PHOSPHORYLASE, USE OF THE SAME AND COMPOSITIONS THAT CONTAIN THEM.
ES2186015T3 (en) DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL.
AR023423A1 (en) ADAMANTAN DERIVATIVES, PROCEDURES FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES
CR20120007A (en) 2-INDOLINONES REPLACED WITH PROTEINQUINASE INHIBITING PIRROLS (DIVISIONAL EXP. 6728)
ES2191320T3 (en) DERIVATIVES OF PIPERAZINE AND ITS USE AS ANTI-INFLAMMATORY AGENTS.
ECSP055609A (en) &#34;Use of IkB-kinase inhibitors for the treatment of pain&#34;
PA8462401A1 (en) DERIVATIVES OF THENOPyrimidine AND THENOPyridine USEFUL AS ANTI-CANCER AGENTS
ES2191152T3 (en) COMBINED THERAPY FOR THE TREATMENT OF PSYCHOSIS.
GT199800106A (en) AZETIDINS.
ES2157524T3 (en) DISELENUROS AND SELENOSULFURES USED AS ANTIOXIDANT AGENTS.
ES2189072T3 (en) NEW BENZO-HETEROCICLIC CYCLALKINS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2060076T3 (en) NEW TETRALINE DERIVATIVES.
ES2175661T3 (en) DERIVATIVES OF ISOFLAVONA, PROCEDURES FOR THE PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2155187T3 (en) BICYCLE ANTAGONISTS OF TAQUICINAS, PREPARATION OF THESE ANTAGONISTS AND ITS USE IN PHARMACEUTICAL COMPOUNDS.
MX9207264A (en) SULFONIMIDAMIDE COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM
BR9904146A (en) Therapeutic combinations that include a selective modulator of estrogen and protaglandin e2 receptors.
ECSP982554A (en) PROSTAGLANDIN AGONISTS
ECSP982698A (en) PROSTAGLANDIN AGONISTS
UY26651A1 (en) COMBINED THERAPY FOR OSTEOPOROSIS